NASDAQ:MGRX Mangoceuticals (MGRX) Stock Price, News & Analysis $0.43 +0.01 (+2.39%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.41▼$0.4550-Day Range$0.25▼$0.5252-Week Range$0.14▼$1.59Volume2.09 million shsAverage Volume2.98 million shsMarket Capitalization$10.62 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Mangoceuticals alerts: Email Address Mangoceuticals MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy4.71% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.28Based on 3 Articles This WeekInsider TradingSelling Shares$5,138 Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.60 out of 5 starsMedical Sector880th out of 936 stocksMiscellaneous Health & Allied Services, Not Elsewhere Classified Industry9th out of 9 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Mangoceuticals.Read more about Mangoceuticals' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.71% of the float of Mangoceuticals has been sold short.Short Interest Ratio / Days to CoverMangoceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Mangoceuticals has recently increased by 430.83%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMangoceuticals does not currently pay a dividend.Dividend GrowthMangoceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MGRX. Previous Next 2.4 News and Social Media Coverage News SentimentMangoceuticals has a news sentiment score of 0.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Mangoceuticals this week, compared to 1 article on an average week.Search Interest6 people have searched for MGRX on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mangoceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,138.00 in company stock.Percentage Held by Insiders39.30% of the stock of Mangoceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions56.72% of the stock of Mangoceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Mangoceuticals' insider trading history. Previous Next 0.0 Earnings and Valuation Price to Book Value per Share RatioMangoceuticals has a P/B Ratio of 10.70. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Mangoceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Find out details on these three critical Nvidia partners immediately. About Mangoceuticals Stock (NASDAQ:MGRX)Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.Read More MGRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MGRX Stock News HeadlinesJuly 24 at 8:15 AM | globenewswire.comMangoRx Initiates Efficacy Studies on its Patented Respiratory Illness Prevention TechnologyJuly 18, 2024 | globenewswire.comMangoceuticals CEO Jacob Cohen Featured on Benzinga All-AccessJuly 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 16, 2024 | globenewswire.comMangoRx Secures DEA Approval for Proprietary HIPAA-Compliant Operating System via SurescriptsJuly 12, 2024 | globenewswire.comMangoRx Appoints Dr. Douglas Christianson, N.D. as Director of the Medical Research and Product Innovation DepartmentJuly 11, 2024 | globenewswire.comMangoRx Announces Strategic Partnership for Expansion into Asia Pacific and Key Emerging MarketsJune 6, 2024 | globenewswire.comMangoRx Receives Notice of Acceptance for Patent Application in Australia for Respiratory Illness and Preventive Care TechnologyJune 4, 2024 | globenewswire.comMangoRx Receives Patent Notice of Allowance in Japan for Revolutionary Preventive Care Technology Acquired from Intramont TechnologiesJuly 26, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.May 28, 2024 | globenewswire.comMangoceuticals, Inc. Announces Completion of First Batch of Mango ED Products for Marketing and Distribution in Mexico and Latin American MarketsMay 23, 2024 | globenewswire.comMangoRx Engages Renown International Digital and Performance Marketing Company Crakmedia to Champion its Digital Marketing EffortsMay 23, 2024 | investorplace.comMove Over Ozempic! 3 New GLP-1 Drugs and Products Coming Soon.May 21, 2024 | investorplace.comWhy Is Mangoceuticals (MGRX) Stock Up 130% Today?May 21, 2024 | finanznachrichten.deMangoceuticals, Inc.: MangoRx to Introduce Oral Semaglutide and Tirzepatide in Response to Increasing Patient Demand for GLP-1 MedicationsMay 21, 2024 | msn.comMangoceuticals Develops Oral GLP-1s: Stock SoarsMay 21, 2024 | globenewswire.comMangoRx to Introduce Oral Semaglutide and Tirzepatide in Response to Increasing Patient Demand for GLP-1 MedicationsMay 17, 2024 | finanznachrichten.deMangoceuticals, Inc.: MangoRx Reports Revenue Growth of 108% in Q1 2024 Fueled by Amplified Customer Acquisition and Early Market PenetrationMay 16, 2024 | investorplace.comMGRX Stock Earnings: Mangoceuticals Reported Results for Q1 2024See More Headlines Receive MGRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mangoceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today7/26/2024Next Earnings (Estimated)7/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Miscellaneous health & allied services, not elsewhere classified Sub-IndustryN/A Current SymbolNASDAQ:MGRX CUSIPN/A CIK1938046 Webwww.mangorx.com Phone833-626-4679FaxN/AEmployees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,210,000.00 Net Margins-1,068.72% Pretax Margin-1,068.60% Return on Equity-864.10% Return on Assets-577.68% Debt Debt-to-Equity RatioN/A Current Ratio0.07 Quick Ratio0.06 Sales & Book Value Annual Sales$730,000.00 Price / Sales14.55 Cash FlowN/A Price / Cash FlowN/A Book Value$0.04 per share Price / Book10.70Miscellaneous Outstanding Shares24,820,000Free Float15,065,000Market Cap$10.62 million OptionableNot Optionable Beta1.96 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. Eugene M. Johnston (Age 60)Chief Financial Officer Comp: $14kMs. Amanda Elizabeth Hammer (Age 38)Chief Operating Officer Comp: $105.42kKey CompetitorsOntrakNASDAQ:OTRKBioRestorative TherapiesNASDAQ:BRTXMarpaiNASDAQ:MRAIGreenbrook TMSNASDAQ:GBNHFGlobal Cord BloodNYSE:CORBFView All CompetitorsInsidersAlex P HamiltonSold 16,574 sharesTotal: $5,137.94 ($0.31/share)View All Insider Transactions MGRX Stock Analysis - Frequently Asked Questions How have MGRX shares performed this year? Mangoceuticals' stock was trading at $0.2769 at the beginning of the year. Since then, MGRX shares have increased by 54.6% and is now trading at $0.4280. View the best growth stocks for 2024 here. When did Mangoceuticals IPO? Mangoceuticals (MGRX) raised $5 million in an initial public offering (IPO) on Tuesday, March 21st 2023. The company issued 1,300,000 shares at $4.00 per share. Boustead Securities acted as the underwriter for the IPO. How do I buy shares of Mangoceuticals? Shares of MGRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MGRX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mangoceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mangoceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MGRX Stock Alerts